Bradley S. Galer Buys 1,346 Shares of Zogenix, Inc. (ZGNX) Stock

Zogenix, Inc. (NASDAQ:ZGNX) EVP Bradley S. Galer bought 1,346 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were purchased at an average price of $36.59 per share, for a total transaction of $49,250.14. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Zogenix, Inc. (NASDAQ:ZGNX) remained flat at $$37.75 during midday trading on Friday. The company had a trading volume of 1,500,000 shares, compared to its average volume of 813,627. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23. Zogenix, Inc. has a 1 year low of $7.70 and a 1 year high of $42.60.

ZGNX has been the topic of a number of recent analyst reports. Mizuho initiated coverage on shares of Zogenix in a research note on Wednesday, September 6th. They set a “buy” rating and a $28.00 target price on the stock. ValuEngine cut shares of Zogenix from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Stifel Nicolaus restated a “buy” rating and set a $55.00 target price (up previously from $26.00) on shares of Zogenix in a research note on Friday, September 29th. Zacks Investment Research upgraded shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, William Blair upgraded shares of Zogenix from a “market perform” rating to an “outperform” rating in a research note on Friday, September 29th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $42.67.

Several institutional investors have recently added to or reduced their stakes in ZGNX. Vanguard Group Inc. raised its position in shares of Zogenix by 7.8% during the first quarter. Vanguard Group Inc. now owns 974,948 shares of the company’s stock valued at $10,578,000 after buying an additional 70,617 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Zogenix by 12.8% during the first quarter. Geode Capital Management LLC now owns 196,793 shares of the company’s stock valued at $2,135,000 after buying an additional 22,407 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Zogenix by 89.4% during the first quarter. Dimensional Fund Advisors LP now owns 410,641 shares of the company’s stock valued at $4,455,000 after buying an additional 193,827 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Zogenix by 17.0% during the first quarter. Metropolitan Life Insurance Co. NY now owns 19,734 shares of the company’s stock valued at $214,000 after buying an additional 2,864 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Zogenix during the second quarter valued at approximately $272,000. Hedge funds and other institutional investors own 73.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/12/17/bradley-s-galer-buys-1346-shares-of-zogenix-inc-zgnx-stock.html.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply